Concepedia

Anjaneya Chimalakonda

AC

Statistics

Publications

23

Citations

1.4K

H-Index

16

Active since

2002

Affiliations

Bristol-Myers Squibb (United States)(Current)

Texas Tech University

Texas Tech University Health Sciences Center

Biocon (India)

Bristol-Myers Squibb (India)

Anjaneya Chimalakonda is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacy, and drug discovery.

Publications per year

2002–2024

23

Publications

23

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 369 citations · Full text

, , +15

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 282 citations

, , +14

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Anjaneya Chimalakonda, James R. Burke, Lihong Cheng et al. · Dermatology and Therapy · 2021 · 125 citations · Full text

, , +16

Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

Tatyana Zvyaga, Shu‐Ying Chang, Cliff Chen et al. · Drug Metabolism and Disposition · 2012 · 123 citations

, , +16

Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir

Makonen Belema, Van N. Nguyen, Carol Bachand et al. · Journal of Medicinal Chemistry · 2014 · 87 citations · Full text

, , +17

1–5 of 23